A recent study published in the BMJ has sparked a crucial conversation about weight-loss medications and their long-term effectiveness. The findings reveal a concerning trend: when patients stop taking these drugs, they rapidly regain the weight they lost, and the health benefits achieved during treatment quickly fade away.
Researchers from the University of Oxford analyzed the impact of discontinuing weight-loss medications, specifically focusing on GLP-1 receptor agonists (GLP-1 RAs). The results were eye-opening. On average, patients regained weight at a rate of 0.4 kg per month after stopping the drugs, and modelling suggests that all lost weight is likely to be regained within just 1.7 years.
But here's where it gets controversial: the study also found that improvements in cardiometabolic risk markers, such as blood pressure, cholesterol, and diabetes risk, returned to pre-treatment levels within a mere 14 months of discontinuation.
And this is the part most people miss: weight regain occurred almost four times faster after stopping pharmacological treatment compared to behavioral weight-loss programs based on diet and physical activity. This was true regardless of the initial amount of weight lost.
Associate Professor Dominika Kwasnicka, a behavioral scientist and public health researcher at the University of Melbourne, highlights the behavioral aspect of obesity. "Obesity is a chronic condition shaped by behaviors and environments, and ongoing support is crucial," she explains.
"While medications can be effective during use, they don't establish the necessary behavioral or systemic changes to sustain weight loss over time," Kwasnicka adds.
The study's implications are far-reaching, especially as the use of GLP-1 receptor agonists continues to rise in primary care. Professor Kwasnicka emphasizes the importance of long-term planning and comprehensive models of care that include behavioral support and realistic discussions about treatment duration.
GLP-1 RAs, such as semaglutide and tirzepatide, have indeed transformed obesity care by enabling significant weight loss and short-term metabolic improvements. However, real-world evidence suggests that around half of patients discontinue GLP-1 RA therapy within 12 months, often due to cost, tolerability, or the expectation of short-term treatment.
The analysis, which included 37 randomized and observational studies involving 9341 adults, compared weight-loss medications with placebo or non-drug behavioral interventions. While the study had some limitations, such as a limited number of studies including newer GLP-1 agents and follow-up beyond 12 months, the consistent results across three analytical approaches strengthen the confidence in the findings.
The authors caution against relying solely on weight-management medications for short-term benefits and emphasize the need for cost-effective strategies to support long-term weight control. They argue that pharmacotherapy alone is unlikely to be sufficient for sustained benefits, and primary prevention remains critical.
In a linked editorial, Associate Professor Qi Sun from the Channing Division of Network Medicine at Harvard Medical School, raises doubts about the idea of GLP-1 receptor agonists as a definitive cure for obesity. He suggests that healthy dietary and lifestyle practices should remain the foundation of obesity management, with medications used as adjuncts rather than replacements.
Professor Sun writes, "The results are not surprising given that reduced adherence to, or cessation of, dietary and lifestyle interventions leads to similar patterns of weight regain. Nevertheless, the study findings cast doubt on the notion that GLP-1 receptor agonists are a perfect cure for obesity."
He further emphasizes the importance of public health measures, such as taxation on sugary beverages and subsidies for fresh produce, to facilitate adherence and improve diet quality.
Professor John B Dixon from the Iverson Health Innovation Research Institute agrees, stating that the analysis highlights the data we've been aware of for years. He adds, "False dichotomies dominate much of the thinking, and you can see them emerging in this review."
This study serves as a reminder that while weight-loss medications can be a valuable tool, they are not a standalone solution. A comprehensive approach that includes behavioral support, lifestyle changes, and long-term planning is essential for sustainable weight management and improved health outcomes.
